Orexigen endorsement raises expectations on obesity drug deals

An FDA advisory panel endorsement can make a big difference for a biotech company, especially if the vote puts you in the lead of a hotly contested drug development race.

Assessing the impact on Orexigen ($OREX) after its surprising victory for the obesity drug Contrave in the wake of two negative votes for its competitors, the Wall Street Journal notes that the endorsement sets the stage for a potentially lucrative pact covering Asia and Europe. And now the spotlight also shifts to another Orexigen weight-loss drug that's not so far advanced. Can Empatic do better-much, much better-than the $50 million signing fee Orexigen earned from Takeda on their Contrave deal?

The Journal goes on to note that everyone in the weight-loss field-including Neurosearch and Vivus--will likely benefit from the vote. This was the first endorsement of an obesity drug in 13 years, proving that it may be possible to actually make it to the marketplace with a blockbuster therapy. And that may spur some big players to the bargaining table.

Orexigen CEO Michael Narachi, meanwhile, is sounding much bolder about Contrave's prospects at the FDA now that the advisers have weighed in. Any possible FDA delay "will just take us out to middle of next year, so we feel good about all of our options," he told analysts on Wednesday.

- read the Wall Street Journal piece
- here's the Reuters report

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.